AmpliPhi Biosciencess C3J Logo

Armata has joined together two seasoned drug development teams, AmpliPhi Biosciences and C3J Therapeutics, to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives.

Armata Pharmaceuticals
Enter

STAMP Platform

Specifically Targeted Antimicrobial Peptide (STAMP) Platform

Armata is the worldwide, exclusive licensee from UCLA of the STAMP (Specifically Targeted Antimicrobial Peptides) Platform.

STAMPs are designed by mining bacterial genomes for targeting domains that confer pathogen-specific killing activity. An antimicrobial peptide is then linked to the targeting domain allowing the antimicrobial activity to be directed to a pathogen of choice within a microbial community. STAMPs drive reengineering of the human microbiome by selectively eliminating targeted pathogens that drive microbial dysbiosis; healthy flora are preserved offering long-term protection from recolonization. This targeted approach represents an enormous improvement over broad-spectrum antibiotics that indiscriminately kill both beneficial and pathogenic bacteria.

STAMP platform proof-of-concept has been demonstrated with the lead STAMP, C16G2, advancing to Phase 2 clinical trials (under US IND). Armata is developing an engineered S. mutans phage product for the treatment of dental caries.